查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046057

精準精神科市場－全球產業規模、佔有率、趨勢、機會、預測：生物標記、樣本、技術、應用、終端用戶、區域及競爭格局，2021-2031年

Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Biomarkers, By Sample, By Technology, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球精準精神科市場預計將從 2025 年的 12.7 億美元成長到 2031 年的 29.3 億美元，複合年成長率達到 14.95%。

這種醫療方法將個體的生物學數據（例如基因和代謝生物標記）與臨床資訊結合，從而實現個人化的精神健康治療。其主要成長要素包括複雜精神障礙在全球日益普遍，以及基因測序技術的進步，使得患者分層更加精準。專注於新型治療標靶的研發投入激增，進一步推動了這一成長，預計到2025年，將有超過160種精神健康治療方法正在研發中。然而，仍有許多挑戰。其中包括將基因譜分析和數據分析等精準醫療工具整合到醫療基礎設施中需要大量的資金投入，這可能會限制其普及和應用，尤其是在資源匱乏的醫療體系中。

市場概覽
預測期 2027-2031
市場規模：2025年 12.7億美元
市場規模：2031年 29.3億美元
複合年成長率：2026-2031年 14.95%
成長最快的細分市場 基因
最大的市場 北美洲

市場促進因素

人工智慧和機器學習在診斷領域的融合正在變革精準精神病學市場。透過分析大量資料集，識別個別患者的治療反應；並透過整合基因組學、轉錄組學和臨床數據，建構生物學檢驗的治療方案。人工智慧驅動的精準醫療平台正迅速實現商業性擴張，例如，Tempus AI等公司報告稱，在2025年第二季度，其收入大幅成長至3.146億美元，同比成長89.6%，這主要得益於基因組分析和資訊服務的應用。同時，隨著臨床醫生致力於最佳化藥物選擇並減少藥物不良反應，藥物基因體學檢測在臨床上的應用日益廣泛，也推動了市場成長。預計到2025年，全球將有超過10億人患有精神疾病。這些檢測分析影響藥物代謝的基因變異，從而減少低效的試驗誤處方箋。這一點從以下事實可以明顯看出：儘管面臨報銷方面的挑戰，Myread Genetics 的 GeneSight 檢測在 2025 年第三季仍同比成長了 8%。

市場挑戰

精準精神醫學市場擴張面臨的主要挑戰之一是整合相關工具所需的龐大資本投入。該領域依賴先進的基因測序和複雜的數據分析，這兩項技術都需要昂貴的技術基礎設施和專業人員。這些高成本構成了准入壁壘，尤其對於預算有限的發展中地區醫療機構和公共醫療系統而言，導致全球市場分散，並被資金雄厚的私立機構所主導。全球精神衛生保健資金嚴重不足進一步加劇了這個問題。預計2025年，政府在精神健康方面的支出中位數僅佔醫療總預算的2%。這種長期資金不足直接阻礙了醫療系統採用和維護必要的先進診斷工具，從而減緩了市場成長，並限制了個人化治療策略的廣泛應用。

市場趨勢

精準醫療框架在迷幻藥療法中的應用是關鍵趨勢。這標誌著治療方案從廣譜給藥轉向基於生物標記的方案。具體而言，該方案利用基因和神經生理數據來識別最有可能從裸蓋菇素和神經塑性劑等化合物中獲益的患者，並最佳化療效和安全性。高價值交易凸顯了商業性對此方法的信心，例如艾伯維公司於2025年8月以高達12億美元的價格收購了吉爾伽美甚製藥公司的精準迷幻藥計畫。同時，穿戴式裝置和行動裝置的普及應用，正在為持續、客觀的病患監測建立新的標準。這使得臨床醫生能夠收集即時行為數據（睡眠、活動、社交互動等），並創建詳細的數位表現型，以補充傳統的評估方法。這種對真實世界數據的縱向整合，有助於早期發現復發並完善個人化治療方案。這項調查方法得到了像 Alto Neuroscience 這樣的專業公司的持續資助，該公司截至 2025 年第三季度擁有 1.383 億美元的現金，用於推進精準精神病學平台的開發，該平台整合了來自穿戴式設備的測量數據。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：精準精神醫學的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 生物標記特異性（基因與蛋白質）
    • 依檢體類型（血液來源與非血液來源）
    • 依技術（定序、聚合酵素鏈鎖反應、微陣列、免疫檢測等）
    • 按應用領域（阿茲海默症、帕金森氏症、自閉症、憂鬱症等）
    • 依最終使用者（醫院/診所、學術/研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美精準精神醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲精準精神醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區精準精神醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲精準精神醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲精準精神醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球精準精神醫學市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Johnson & Johnson Services, Inc.
  • Roche Holding AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • H. Lundbeck A/S
  • Helsinn Group
  • Takeda Pharmaceutical Company Limited
  • Otsuka Holdings Co., Ltd.
  • BioXcel Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 12983

The global precision psychiatry market is projected to grow from USD 1.27 billion in 2025 to USD 2.93 billion by 2031, achieving a 14.95% CAGR. This medical approach integrates individual biological data, like genetic and metabolic biomarkers, with clinical information to customize mental health treatments. Key growth drivers include the rising global prevalence of complex mental disorders and the advancement of genomic sequencing, which enables more precise patient stratification. A surge in R&D for novel therapeutic targets, with over 160 mental health treatments in development in 2025, further supports this growth. However, a significant challenge remains: the high capital investment required to integrate precision tools, such as genetic profiling and data analysis, into healthcare infrastructures, potentially limiting accessibility and widespread adoption, especially in resource-constrained systems.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.27 Billion
Market Size 2031USD 2.93 Billion
CAGR 2026-203114.95%
Fastest Growing SegmentGenetic
Largest MarketNorth America

Market Driver

The integration of AI and machine learning in diagnostics is reshaping the precision psychiatry market by enabling the analysis of vast datasets to identify patient-specific therapeutic responses, synthesizing genomic, transcriptomic, and clinical data for biologically validated treatment protocols. The rapid commercial expansion of AI-enabled precision medicine platforms is evident, with companies like Tempus AI reporting significant revenue increases, such as an 89.6% year-over-year growth to $314.6 million in Q2 2025 driven by genomics and data services adoption. Concurrently, the increasing clinical adoption of pharmacogenomic testing is driving market growth, as clinicians aim to optimize medication selection and reduce adverse drug reactions for the over 1 billion people worldwide living with a mental disorder in 2025. These tests analyze genetic variations affecting drug metabolism, reducing inefficient trial-and-error prescribing, as demonstrated by an 8% year-over-year growth in Myriad Genetics' GeneSight test volume in Q3 2025 despite reimbursement challenges.

Market Challenge

A significant challenge to the precision psychiatry market's expansion is the substantial capital investment required for integrating its tools. This field depends on advanced genomic sequencing and complex data analysis, both demanding costly technological infrastructure and specialized staff. Such high costs create a barrier to entry, especially for providers in developing regions or publicly funded systems with limited budgets, leading to adoption primarily by well-funded private institutions and fragmenting the global market. This issue is intensified by severe underfunding in global mental healthcare; in 2025, median government spending on mental health was only 2% of total health budgets. This chronic underinvestment directly hinders healthcare systems from acquiring and maintaining necessary sophisticated diagnostic tools, thereby decelerating market growth and limiting the widespread application of personalized therapeutic strategies.

Market Trends

A significant trend is the application of precision medicine frameworks to psychedelic therapeutics, moving towards biomarker-guided protocols rather than broad-spectrum administration. This involves using genetic and neurophysiological data to identify patients most likely to benefit from compounds like psilocybin and neuroplastogens, optimizing efficacy and safety. Commercial confidence in this approach is highlighted by high-value deals, such as AbbVie's acquisition of Gilgamesh Pharmaceuticals' precision psychedelic program for up to $1.2 billion in August 2025. Concurrently, the proliferation of digital phenotyping through wearables and mobile devices is setting a new standard for continuous, objective patient monitoring. This allows clinicians to collect real-time behavioral data (e.g., sleep, activity, social interaction) to create detailed digital phenotypes that complement traditional assessments. This integration of longitudinal real-world data facilitates early relapse detection and refines personalized treatment plans, a methodology supported by sustained funding for specialized firms like Alto Neuroscience, which maintained $138.3 million in cash in Q3 2025 to advance its precision psychiatry platform incorporating wearable metrics.

Key Market Players

  • Johnson & Johnson Services, Inc.
  • Roche Holding AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • H. Lundbeck A/S
  • Helsinn Group
  • Takeda Pharmaceutical Company Limited
  • Otsuka Holdings Co., Ltd.
  • BioXcel Therapeutics, Inc.
  • Neurocrine Biosciences, Inc.

Report Scope

In this report, the Global Precision Psychiatry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Psychiatry Market, By Biomarkers

  • Genetic
  • Protein

Precision Psychiatry Market, By Sample

  • Blood Based
  • Non-Blood-Based

Precision Psychiatry Market, By Technology

  • Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Immunoassay
  • Others

Precision Psychiatry Market, By Application

  • Alzheimer's Disease
  • Parkinson's Disease
  • Autism
  • Depression
  • Others

Precision Psychiatry Market, By End User

  • Hospital & Clinics
  • Academic & Research Institutions
  • Others

Precision Psychiatry Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Psychiatry Market.

Available Customizations:

Global Precision Psychiatry Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Psychiatry Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Biomarkers (Genetic v/s Protein)
    • 5.2.2. By Sample (Blood Based v/s Non-Blood-Based)
    • 5.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 5.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 5.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Precision Psychiatry Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Biomarkers
    • 6.2.2. By Sample
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Precision Psychiatry Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Biomarkers
        • 6.3.1.2.2. By Sample
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Precision Psychiatry Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Biomarkers
        • 6.3.2.2.2. By Sample
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Precision Psychiatry Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Biomarkers
        • 6.3.3.2.2. By Sample
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Precision Psychiatry Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Biomarkers
    • 7.2.2. By Sample
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Precision Psychiatry Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Biomarkers
        • 7.3.1.2.2. By Sample
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Precision Psychiatry Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Biomarkers
        • 7.3.2.2.2. By Sample
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Precision Psychiatry Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Biomarkers
        • 7.3.3.2.2. By Sample
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Precision Psychiatry Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Biomarkers
        • 7.3.4.2.2. By Sample
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Precision Psychiatry Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Biomarkers
        • 7.3.5.2.2. By Sample
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia Pacific Precision Psychiatry Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Biomarkers
    • 8.2.2. By Sample
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Precision Psychiatry Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Biomarkers
        • 8.3.1.2.2. By Sample
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Precision Psychiatry Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Biomarkers
        • 8.3.2.2.2. By Sample
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Precision Psychiatry Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Biomarkers
        • 8.3.3.2.2. By Sample
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Precision Psychiatry Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Biomarkers
        • 8.3.4.2.2. By Sample
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Precision Psychiatry Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Biomarkers
        • 8.3.5.2.2. By Sample
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Middle East & Africa Precision Psychiatry Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Biomarkers
    • 9.2.2. By Sample
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Precision Psychiatry Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Biomarkers
        • 9.3.1.2.2. By Sample
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Precision Psychiatry Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Biomarkers
        • 9.3.2.2.2. By Sample
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Precision Psychiatry Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Biomarkers
        • 9.3.3.2.2. By Sample
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. South America Precision Psychiatry Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Biomarkers
    • 10.2.2. By Sample
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Precision Psychiatry Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Biomarkers
        • 10.3.1.2.2. By Sample
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Precision Psychiatry Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Biomarkers
        • 10.3.2.2.2. By Sample
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Precision Psychiatry Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Biomarkers
        • 10.3.3.2.2. By Sample
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Precision Psychiatry Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Johnson & Johnson Services, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Roche Holding AG
  • 15.3. Eli Lilly and Company
  • 15.4. Pfizer Inc.
  • 15.5. H. Lundbeck A/S
  • 15.6. Helsinn Group
  • 15.7. Takeda Pharmaceutical Company Limited
  • 15.8. Otsuka Holdings Co., Ltd.
  • 15.9. BioXcel Therapeutics, Inc.
  • 15.10. Neurocrine Biosciences, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer